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INTRODUCTION
Gallbladder cancer (GBC), though generally considered rare, 
is the most common malignancy of the biliary tract, accounting 
for 80–95% of biliary tract cancers. GBC is considered the most 
aggressive of biliary cancers with the shortest survival time.1 
Complete surgical resection offers the only chance for a cure; 
however, only 10% of patients with GBC present with early-
stage disease and are considered surgical candidates. Advanced 
GBC is characterized by early local invasion, extensive regional 
lymph node metastasis, vascular encasement, and distant me-
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Purpose: This study aimed to determine the prognostic value of new quantitative parameters of 18F-fluorodeoxyglucose positron 
emission tomography/computed tomography (18F-FDG PET/CT), including metabolic tumor volume (MTV), in patients with lo-
cally advanced and metastatic gallbladder cancer (GBC).
Materials and Methods: In total, 83 patients initially diagnosed with locally advanced and metastatic GBC and who underwent 
18F-FDG PET/CT at the time of initial diagnosis were retrospectively reviewed. The metabolic volume-based PET parameters of pri-
mary tumors and metastatic lesions were measured, including maximum and average standardized uptake values (SUV), MTV, 
and total lesion glycolysis. An overall survival (OS) analysis was performed using the Kaplan-Meier method with PET and clinical 
parameters. A Cox proportional hazards regression analysis was performed to determine independent prognostic factors.
Results: In univariate analysis, pathologic differentiation (p<0.001), performance status (PS; p=0.003), C-reactive protein (CRP) 
level (p=0.009), and PET-related SUVmt max (the highest SUV among the metastatic lesions) (p=0.040) and MTVtotal (the sum of the 
MTVs of both the primary and metastatic lesions) (p=0.031), were significant for OS. In multivariate analysis, MTVtotal (hazard ra-
tio: 2.07; 95% confidence interval: 1.23–3.48; p=0.006) remained significant for the prediction of OS, as did differentiation 
(p=0.001), PS (p=0.001), and CRP (p=0.039).  
Conclusion: In locally advanced and metastatic GBC, volume-based PET/CT parameters of the total tumor burden of malignan-
cy, such as MTVtotal, were found to be useful for the identification of patients with poor prognosis.
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tastasis, leading to a poor prognosis from unresectable or met-
astatic disease.1,2 
Accurate stratification for outcome prediction based only on 
anatomic stage is difficult. A more accurate and reliable prog-
nostic system incorporating additional features of tumors, 
such as biological and molecular information, may be necessary 
to obtain a better prediction of prognosis and to choose the 
most appropriate treatment modality and follow-up plan for 
locally advanced and metastatic GBC. 18F-fluorodeoxyglucose 
positron emission tomography/computed tomography (18F-
FDG PET/CT) is an increasingly available noninvasive test for 
malignancy based on glucose metabolism. It was recently dem-
onstrated to be valuable for initial staging and for the detection 
of recurrent diseases in many kinds of tumors, including GBC.3 
18F-FDG PET is useful not only for diagnosing and staging, but 
also for evaluating the proliferative activity and malignancy 
grades of tumors reflecting prognosis. The standardized up-
take value (SUV) of the primary tumor, a semi-quantitative pa-
rameter derived from 18F-FDG PET, is a significant prognostic 
factor for various types of cancer.4,5 Despite being a popular 
landmark clinically, this parameter only has a single voxel value 
and cannot be used to indicate the metabolism of the whole tu-
mor and metastatic lesions. In fact, many studies that have in-
dicated SUV as a significant prognostic factor did not analyze 
parameters reflective of tumor volume. Recent studies have re-
ported that volumetric PET parameters, such as metabolic tu-
mor volume (MTV) and total lesion glycolysis (TLG), using a 
threshold-based automatic volume of interest (VOI) were bet-
ter prognostic predictors for survival in patients with malignant 
pleural mesothelioma, esophageal cancer, and advanced head 
and neck squamous cell carcinomas.6-8 There is still little evi-
dence that volumetric PET parameters are significant prognos-
tic predictor in patients with GBC. This study sought to investi-
gate the prognostic value of SUV and volume-based metabolic 
parameters on used 18F-FDG PET/CT in comparison to other 
clinical parameters in patients with advanced and metastatic 
GBC. 
MATERIALS AND METHODS
Patients
A total of 83 patients at Gangnam Severance Hospital with bi-
opsy-proven gallbladder adenocarcinoma who received 18F-
FDG PET/CT pretreatment between January 2007 and Decem-
ber 2015 were included in this retrospective study. Exclusion 
criteria were patients with resectable early disease, double-pri-
mary malignancy, previous cholecystectomy, and other histol-
ogy types, such as cystic neoplasms, neuroendocrine tumors, 
or lymphomas. The Institutional Review Board of Severance 
Hospital, Yonsei University Health System approved this retro-
spective study (IRB Number: 3-2015-0318) and waived the re-
quirement to obtain informed consent.
The medical records of each patient were investigated for sex, 
age, histologic typing, performance status (PS), extrahepatic 
metastases, carcinomatosis, and treatment modality. Histologic 
typing was classified as well, moderately, or poorly differenti-
ated, and PS was classified according to the Eastern Coopera-
tive Oncology Group (ECOG) performance status. Computed 
tomography (CT) of the chest and abdominopelvic cavity, a ra-
dionuclide bone scan, and 18F-FDG PET/CT were performed to 
evaluate locally advanced disease or distant metastasis. Sur-
vival status was retrieved from our medical records or from at-
tempts to contact the patients or their referring physicians. All 
follow-up evaluations ended on December 30, 2015.
18F-FDG PET/CT imaging protocols
Imaging and data acquisition for metabolic parameters was 
conducted using the PET/CT system (Biograph TruePoint 40, 
Siemens Healthcare, Munich, Germany). PET/CT was per-
formed before treatment. The fasting time before the adminis-
tration of 18F-FDG (Nambuk Medical, Seoul, Korea) was at 
least 6 hours, and serum glucose levels were not to have ex-
ceeded 150 mg/dL. After the injection of 5.18 MBq/kg (0.14 
mCi/kg) of 18F-FDG, each patient waited in a warm, quiet, dim 
room for 60 minutes. An initial low-dose CT scan was followed 
by a PET scan from the skull base to the upper thigh level in the 
three-dimensional mode (1.5-min acquisition time per bed), 
and the scanned data were reconstructed using the iterative 
method, ordered subset expectation maximization, using two 
iterations and 21 subsets. Trans-axial spatial resolution of the 
PET system was 5 mm full-width at half maximum at the center 
of the field of view. The matrix size and thickness of the recon-
structed PET image were 128×128 and 5 mm, respectively.
Analysis of PET/CT data
The metabolic parameters from 18F-FDG PET/CT data were 
evaluated by two experienced nuclear medicine physicians 
using dedicated software for the PET/CT workstation (Syngo 
VE32B, Siemens AG, Berlin, Germany). To define the contour-
ing margins around the tumor, SUV >2.5 was used as previous-
ly reported.9 The contour around the target lesions within the 
boundaries was automatically generated and within the con-
tour margin were combined to define the tumor volumes. MTV 
was defined as the sum of metabolic volumes of tumor tissues 
with increased FDG uptake. The SUV threshold value used in 
this study was 50% of the local maximum SUV intensity, iden-
tified as a reasonable value in phantom studies.9,10 We selected 
lesions with SUV >2.5, and selected regions within lesions 
with a SUV intensity greater than 50% for quantitative MTV 
measurement. TLG was representative of the metabolic activ-
ity throughout the entire tumor and was calculated by multi-
plying MTV and the mean SUV (SUVmean) of the MTV. Appro-
priately sized spherical VOIs, including each targeted locally 
advanced and metastatic lesion, were created by considering 
the tumor location in the trans-axial, sagittal, and coronal 
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planes. Physiologic activities in the adjacent liver, stomach, 
and bowel loops were avoided. These parameters, SUV, and 
MTV were automatically calculated by the Syngo software (Sie-
mens, Erlangen, Germany). 
Statistical analysis
The primary end point of this study was overall survival (OS), 
which was measured from the date of diagnosis of GBC to the 
date of death from any cause. The Kaplan-Meier method was 
used for survival analysis, and the difference in the rate was 
compared using a log-rank test. A prognostic model was es-
tablished by finding all of the variables that significantly influ-
enced OS (p<0.05) in univariate analysis. The clinical variables 
included in the univariate analysis were age, sex, pathologic 
differentiation, ECOG PS, extrahepatic metastases, carcinoma-
tosis, C-reactive protein (CRP), and tumor markers [serum car-
cinoembryonic antigen (CEA) and carbohydrate antigen 19-9 
(CA19-9) levels]. Metabolic PET variables included the highest 
SUV of the locally advanced lesion (SUVLA max), the highest 
SUV among the distant metastatic lesions (SUVmt max), the 
MTV of the locally advanced lesion (MTVLA), the sum of the 
MTVs of all metastatic lesions (MTVmt total), the highest MTV 
among the metastatic lesions (MTVmt max), the sum of the MTVs 
of both the locally advanced and metastatic lesions (MTVtotal), 
the TLG of the locally advanced lesion (TLGLA), the sum of the 
TLGs of all metastatic lesions (TLGmt total), the highest TLG 
among the TLGmt (TLGmt max), and the sum of the TLGs of both 
locally advanced and metastatic lesions (TLGtotal). For metabol-
ic parameters, the median value was used as the cut-off; for tu-
mor markers, the normal range was used. A Cox proportional 
hazards regression analysis was performed to determine inde-
pendent prognostic factors. Statistical analyses were per-
formed using IBM SPSS Statistics for Windows, Version 23 (IBM 
Corp., Armonk, NY, USA). P values <0.05 were considered sig-
nificant.
RESULTS
Patient characteristics
This study included 83 patients. The median clinical follow-up 
period was 9.9 months (range, 0.2–77.2 months). Baseline pa-
tient and tumor characteristics, including age, sex, pathologic 
differentiation, ECOG PS, extrahepatic metastases, carcino-
matosis, CRP, CEA, CA19-9, SUVLA max, SUVmt max, MTVLA, MT-
Vmt total, MTVmt max, MTVtotal, TLGLA, TLGmt total, TLGmt max, TLGtotal 
levels, and treatment modality are presented in Table 1.
Prognostic factors evaluated in univariate analysis
The cut-off levels of serum CRP, CEA, and CA19-9 levels were 
set to 6 mg/L, 5 ng/mL, and 24 U/mL, respectively, based on the 
normal values at our institution. The median age of 67 years 
was used as a cut-off. The median values of the PET and meta-
Table 1. Baseline Patient Characteristics with Positron Emission To-
mography Parameters of Primary and Metastatic Lesions 
Characteristics Value (n=83)
Age (yr)
Median 67
Mean (range) 65 (30–88)
Sex
Male 44 (53)
Female 39 (47)
Differentiation
Well, moderate 49 (58.3)
Poor 34 (40.5)
Performance status
ECOG 0, 1 42 (50.0)
ECOG 2, 3 41 (48.8)
Extrahepatic metastases
No 29 (34.5)
Yes 54 (64.3)
Carcinomatosis
Yes 19 (22.6)
No 64 (76.2)
CRP
Normal (range) 6 mg/dL (0–222.7 mg/dL)
≤6 mg/L 33 (39.3)
>6 mg/L 50 (59.5)
CEA
Normal (range) 5 ng/mL (0.4–640.8 ng/mL)
≤5 ng/mL 40 (47.6)
>5 ng/mL 43 (51.2)
CA19-9
Normal (range) 24 U/mL (0.8–25160.0 U/mL)
≤24 U/mL 24 (28.6)
>24 U/mL 59 (70.2)
SUVLA max
Median (range) 8.31 (3.15–35.56)
Mean       9.73
SUVmt max
Median (range) 7.74 (0–124.57)
Mean     10.39
MTVLA (cm3)
Median (range) 153.60 (2.26–2175.81)
Mean   344.68
MTVmt total (cm3)
Median (range) 109.29 (0–1363.97)
Mean   197.97
MTVmt max (cm3)
Median (range) 26.31 (0–1005.36)
Mean   115.18
MTVtotal (cm3)
Median (range) 350.77 (0–3116.24)
Mean   551.7
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bolic parameters were as follows: SUVLA max, 8.31; SUVmt max, 
7.74; MTVLA, 153.60 cm3; MTVmt total, 109.29 cm3; MTVmt max, 
26.31 cm3; MTVtotal, 350.77 cm3; TLGLA, 829.24 g; TLGmt total, 
392.50 g; TLGmt max, 102.82 g; and TLGtotal, 2191.76 g. The pa-
tients were divided into two groups according to the median 
value of the parameters. Overall, 46 patients were younger than 
the median age of 67 years; 37 patients were older. Univariate 
analysis demonstrated that pathologic differentiation 
(p<0.001), PS (p=0.003), CRP level (p=0.009), SUVmt max (p= 
0.040), and MTVtotal (p=0.031) were significantly prognostic. In 
addition, as expected, chemotherapy with gemcitabine and cis-
platin had a significant impact on prognosis (Table 2). 
Prognostic factors evaluated in multivariate analysis
In multivariate analysis of adjusted treatment modalities, patho-
logic differentiation [HR=2.42 (well differentiated and moder-
ately differentiated vs. poorly differentiated); p=0.001], PS [HR= 
2.28 (ECOG 0, 1 vs. 2, 3); p=0.001], CRP (HR=1.73; p=0.039), and 
MTVtotal [HR=2.07 (≤350.77 cm3 vs. >350.77 cm3); p=0.006] 
were independent prognostic factors for the prediction of OS 
(Table 3, Fig. 1). In patients with locally advanced and meta-
static disease, MTVtotal, a volume-based metabolic PET pa-
rameter, was an important independent prognostic factor for 
OS, along with other PET parameters. 
DISCUSSION
There have been various reports on the role of PET/CT in GBC 
Table 1. Baseline Patient Characteristics with Positron Emission To-
mography Parameters of Primary and Metastatic Lesions (Continued)
Characteristics Value (n=83)
TLGLA (g)
Median (range) 829.24 (5.62–16147.31)
Mean 2546.76
TLGmt total (g)
Median (range) 392.50 (0–28170.70)
Mean 1762.47
TLGmt max (g)
Median (range) 102.82 (0–28170.70)
Mean   990.31
TLGtotal (g)
Median (range) 2191.76 (0–28525.03)
Mean 4386.3
Treatment modality
Gemcitabine+cisplatin (n) 62
No treatment (n) 18
Others (n)*   3
ECOG, Eastern Cooperative Oncology Group; CRP, C-reactive protein; CEA, 
carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; SUV, stan-
dardized uptake value; SUVLA max, the highest SUV of the locally advanced le-
sion; SUVmt max, the highest SUV among the distant metastatic lesions; MTV, 
metabolic tumor volume; MTVLA, the MTV of the locally advanced lesion; 
MTVmt total, the sum of the MTVs of all metastatic lesions; MTVmt max, the high-
est MTV among the metastatic lesions; MTVtotal, the sum of the MTVs of both 
the locally advanced and metastatic lesions; TLG, total lesion glycolysis; TL-
GLA, the TLG of the locally advanced lesion; TLGmt total, the sum of the TLGs of 
all metastatic lesions; TLGmt max, the highest TLG among the TLGmt; TLGtotal, the 
sum of the TLGs of both locally advanced and metastatic lesions.
Values are presented as number (percentage) unless otherwise noticed.
*Others, one patient with concurrent chemotherapy (CCRT) using cisplatin, 
one patient with CCRT using fluorouracil, and one patient with radiotherapy 
alone.
Table 2. Univariate Analysis of Prognostic Factors for Survival Outcomes
Parameter HR 95% CI p value
Age 1.01 0.99–1.03 0.388
Sex 0.88 0.55–1.41 0.599
Differentiation 2.57 1.55–4.24 < 0.001
PS (ECOG) 2.04 1.27–3.29 0.003
Extrahepatic metastases 1.66 0.99–2.78 0.054
Carcinomatosis 1.69 0.98–2.93 0.060
CRP 1.94 1.18–3.21 0.009
CEA 1.32 0.82–2.12 0.251
CA19-9 0.62 0.37–1.04 0.072
SUVLA max 1.04 1.00–1.07 0.057
SUVmt max 1.02 1.00–1.04 0.040
MTVLA 1.60 0.99–2.59 0.057
MTVmt total 1.36 0.85–2.18 0.203
MTVmt max 1.10 0.682–1.75 0.716
MTVtotal 1.70 1.05–2.76 0.031
TLGLA 1.50 0.90–2.35 0.128
TLGmt total 1.41 0.88–2.26 0.157
TLGmt max 1.23 0.78–2.00 0.360
TLGtotal 1.50 0.93–2.40 0.098
Treatment modality* 0.44 0.26–0.76 0.003
HR, hazard ratio; CI, confidence interval; PS, performance status; ECOG, East-
ern Cooperative Oncology Group; CRP, C-reactive protein; CEA, carcinoembry-
onic antigen; CA19-9, carbohydrate antigen 19-9; SUV, standardized uptake 
value; SUVpri max, the highest SUV of the primary lesion; SUVmt max, the highest 
SUV among the metastatic lesions; MTV, metabolic tumor volume; MTVpri, 
the MTV of the primary lesion; MTVmt total, the sum of the MTVs of all meta-
static lesions; MTVmt max, the highest MTV among the metastatic lesions; MT-
Vtotal, the sum of the MTVs of both the primary and metastatic lesions; TLG, 
total lesion glycolysis; TLGpri, the TLG of the primary lesion; TLGmt total, the sum 
of the TLGs of all metastatic lesions; TLGmt max, the highest TLG among the 
TLGmt; TLGtotal, the sum of the TLGs of both primary and metastatic lesions.
*Sixty-two patients received gemcitabine plus cisplatin chemotherapy, 18 pa-
tients received no treatment, and 3 patients received concurrent chemother-
apy or radiotherapy alone.  
Table 3. Multivariate Analysis of Prognostic Factors of Survival Outcomes
Parameter HR 95% CI p value
Differentiation 2.42 1.43–4.09 0.001
PS 2.28 1.38–3.77 0.001
CRP 1.73 1.03–2.92 0.039
MTVtotal 2.07 1.23–3.48 0.006
Treatment modality 0.40 0.23–0.71 0.002
HR, hazard ratio; CI, confidence interval; PS, performance status; CRP, C-reac-
tive protein; MTVtotal, the sum of the MTVs of both locally advanced and meta-
static lesions.
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diagnosis. In particular, 18F-FDG PET/CT seems to have a po-
tential role in staging, as these cancers are intensely FDG-avid. 
PET/CT has an overall diagnostic accuracy of 95.9% for the pri-
mary disease and 85.7% and 95.9% for the detection of lymph 
nodes and metastatic lesions, respectively.11 Enhanced utiliza-
tion of glucose than normal tissues, more aggressive malignan-
cies, and higher rates of glycolysis than less malignant or benign 
tumors have been observed in cancer cells.12-14 These glucose 
metabolism differences can be measured quantitatively in vivo 
by PET after FDG administration. 
We investigated the prognostic values of volume-based met-
abolic parameters using 18F-FDG PET/CT in metastatic GBC, 
compared with conventional clinical parameters. Many prog-
nostic factors for advanced and metastatic GBC have been pro-
posed: most are clinico-pathological parameters. Clinical or 
pathologic staging, including tumor extension and nodal in-
volvement, and blood CEA levels have remained good prog-
nostic values for GBC.15-17 However, these parameters cannot 
be categorized in detail or presented as objective numbers in 
unresectable GBC. In other words, a significant prognostic mark-
er that can quantify molecular and metabolic parameters is re-
quired for the treatment decision of GBC patients. 
Several recent studies have investigated the prognostic val-
ue of 18F-FDG PET/CT parameters in GBC patients. Despite an 
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Fig. 1. Kaplan-Meier curves for overall survival based on significant prognostic factors, including (A) pathologic differentiation [HR=2.42 (well differentiat-
ed and moderately differentiated vs. poorly differentiated); p=0.001], (B) performance status [HR=2.28 (ECOG 0, 1 vs. 2, 3); p=0.001], (C) CRP [HR=1.73 (≤6 
mg/dL vs. >6 mg/dL); p=0.039], and (D) MTVtotal [HR=2.07 (≤350.77 cm3 vs. >350.77 cm3); p=0.006] in gallbladder carcinoma. ECOG, Eastern Cooperative On-
cology Group; CRP, C-reactive protein; MTVtotal, the sum of the MTVs of both the locally advanced and metastatic lesions; HR, hazard ratio.
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absence of standardized cut-off values, poorer survival has 
consistently been correlated with a high SUVmax of the primary 
lesion as measured on pretreatment 18F-FDG PET/CT scans of 
biliary tract carcinoma.18 Only one previous study investigated 
the utility of 18F-FDG PET/CT volumetric parameters to predict 
clinical outcomes in GBC. Yoo, et al.19 analyzed the various 
metabolic volume-based PET parameters of primary tumors, 
including maximum and average SUV, MTV, and TLG, mea-
sured on 18F-FDG PET/CT scans of 44 patients with GBC. They 
showed that those with an MTV cut-off of 135 cm3 (p=0.001) and 
a TLG cut-off of 7090 g (p<0.050) had significantly longer OS 
than those with lower MTV and TLG values. In the present 
study, pathologic differentiation, PS, and serum CRP levels 
were significant factors according to univariate analysis, while 
SUV and MTV were significant independent prognostic fac-
tors. MTVtotal was determined to be a meaningful independent 
prognostic factor in multivariate analysis with adjustment for 
treatment modality. 
Histologically, the gallbladder does not have submucosa, 
and the cancer infiltrates directly into the muscularis propria. 
The gallbladder wall is thin, and the cancer is able to easily infil-
trate to adjacent organs, such as the liver, duodenum, and pan-
creas. As GBC is associated with a high rate of local invasion 
and distant metastases, resulting in poor survival, we hypoth-
esized that the metabolic activity of all primary and metastatic 
lesions on 18F-FDG PET/CT scans might be more helpful to 
guide treatment decisions than the primary lesion only. Thus, 
our study included locally advanced and metastatic GBC pa-
tients and measured the MTV and TLG of both metastatic and 
locally advanced primary lesions. In doing so, we deduced 
through multivariate analysis that the total MTV, including 
metastatic lesions, was the most significant prognostic factor.20 
Quantified metabolic activity can provide valuable informa-
tion to help prognosticate and assess treatment response in 
clinical oncology.21 While CT scan and MRI readily reveal the 
anatomic distribution of tumors, they do not permit the quanti-
fication of the metabolic activity of a tumor. Anatomically large 
tumors in CT scan can have low metabolic activity, and small le-
sions of metastases can be highly active. Therefore, it is thought 
that MTV measurement with PET/CT is an important factor 
for prediction of survival prognosis.22,23 While SUVmt max (the 
highest SUV among the metastatic lesions) was significant in 
univariate analysis, it was excluded from multivariate analysis 
because SUVmt max, interpreted as a single voxel value, may not 
reflect the tumor’s general metabolism due to tumor hetero-
geneity. In addition, TLG was not significant for survival pre-
diction: it is calculated by multiplying the tumor volume by the 
SUVmean. Metastatic GBC can show diverse SUVs in both a local-
ly advanced primary lesion and in multiple metastatic lesions. 
Therefore, as the TLG is calculated as the SUVmean, its impor-
tance in survival prediction may be weakened. MTV appeared 
to be more important for prediction of survival prognosis than 
SUV due to the variety of SUVs obtained. 
Our present study had several limitations. First, it was de-
signed as a retrospective study and included a relatively small 
number of patients. Therefore, our results may not be applica-
ble to all patients with locally advanced and metastatic GBC. 
Second, it was difficult to clarify the boundary between the 
primary lesion and liver infiltrative lesion, since GBC readily 
invade the liver. Hence, we defined locally advanced GBC in-
cluding liver invasion and obtained MTV according to locally 
advanced primary lesion. Third, the cut-off value of each PET 
parameter was set to a median value due to a small number of 
samples and a wide range of parameter values. It is necessary 
to find an accurate cut-off value with a larger number of pa-
tients. 
Despite these limitations, our study is the first to demon-
strate the clinical value of volume-based PET parameters of 
GBC in a metastatic clinical setting, and our results support a 
more detailed follow-up or stratification of aggressive therapy 
in high MTVtotal patients due to their poor prognosis. Addi-
tional larger-scale prospective studies using 18F-FDG PET/CT 
are required to validate our results. 
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